Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs Smith & Nephew plc (SNN) Price & Performance

Novartis AGTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Smith & Nephew plc — how do they compare? Novartis AG trades at $152.92 (market cap $295.37B), while Smith & Nephew plc trades at $29.56 (market cap $12.54B). The key difference: Novartis AG is far larger — about 23.6× Smith & Nephew plc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

NVSSNN
Market Cap
$295.37B$12.54B
Sector
HealthHealth
52-Week High
$168.62$38.70
52-Week Low
$119.31$28.73
Enterprise Value
$336.69B$15.57B
Dividend Yield
3.07%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.

Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN